ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · IEX Real-Time Price · USD
17.75
-0.25 (-1.39%)
At close: Jul 19, 2024, 4:00 PM
17.79
+0.04 (0.23%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
ACADIA Pharmaceuticals Stock Forecast
Stock Price Forecast
The 20 analysts with 12-month price forecasts for ACAD stock have an average target of 29.3, with a low estimate of 19 and a high estimate of 42. The average target predicts an increase of 65.07% from the current stock price of 17.75.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ACAD stock from 20 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 6 | 6 | 6 | 6 | 6 |
| Buy | 7 | 7 | 7 | 7 | 8 | 8 |
| Hold | 6 | 6 | 6 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 19 | 19 | 19 | 20 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $30 → $28 | Buy | Maintains | $30 → $28 | +57.75% | Jul 12, 2024 |
| BMO Capital | BMO Capital | Buy Initiates $31 | Buy | Initiates | $31 | +74.65% | Jun 27, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $29 | Buy | Reiterates | $29 | +63.38% | Jun 25, 2024 |
| B of A Securities | B of A Securities | Hold Maintains $26 → $22 | Hold | Maintains | $26 → $22 | +23.94% | May 10, 2024 |
| Needham | Needham | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +69.01% | May 9, 2024 |
Financial Forecast
Revenue This Year
972.94M
from 726.44M
Increased by 33.93%
Revenue Next Year
1.10B
from 972.94M
Increased by 12.65%
EPS This Year
0.60
from -0.37
EPS Next Year
1.15
from 0.60
Increased by 93.61%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.0B | 1.3B | 1.4B | 1.6B | 2.0B |
| Avg | 972.9M | 1.1B | 1.2B | 1.4B | 1.5B |
| Low | 901.1M | 983.1M | 1.1B | 1.2B | 1.2B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 41.8% | 29.9% | 26.6% | 31.5% | 42.4% |
| Avg | 33.9% | 12.6% | 13.0% | 11.7% | 10.2% |
| Low | 24.0% | 1.0% | -2.6% | -5.3% | -11.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.89 | 2.23 | 3.14 | 4.10 | 4.59 |
| Avg | 0.60 | 1.15 | 1.68 | 2.26 | 2.73 |
| Low | 0.28 | 0.51 | 0.47 | 0.60 | 0.80 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 275.3% | 172.3% | 144.1% | 103.2% |
| Avg | - | 93.6% | 45.5% | 34.6% | 20.7% |
| Low | - | -14.4% | -59.2% | -64.4% | -64.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.